

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	To be assigned
Filing Date	
First Named Inventor	Rao et al.
Group Art Unit	To be assigned 1633
Examiner Name	To be assigned Quang Nguyen
Attorney Docket Number	2923-5456.1US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
QW		US- 2002/0012660 A1	01/31/2002	Colman et al.	
		US- 2002/0037281 A1	03/28/2002	Davidson et al.	
		US- 4,350,687	09/21/1982	Lipton et al.	
		US- 4,766,073	08/23/1988	Murray et al.	
		US- 4,801,542	01/31/1989	Murray et al.	
		US- 4,845,075	07/04/1989	Murray et al.	
		US- 4,889,919	12/26/1989	Murray et al.	
		US- 4,997,929	03/05/1991	Collins et al.	
		US- 5,096,825	03/17/1992	Barr et al.	
		US- 5,180,820	01/19/1993	Barde et al.	
		US- 5,229,500	07/20/1993	Barde et al.	
		US- 5,252,479	10/12/1993	Srivastava	
		US- 5,399,346	03/21/1995	Anderson et al.	
		US- 5,413,923	05/09/1995	Kucheralapati et al.	
		US- 5,416,260	05/16/1995	Koller et al.	
		US- 5,438,121	08/01/1995	Barde et al.	
		US- 5,439,818	08/08/1995	Fiddes et al.	
		US- 5,464,764	11/07/1995	Capecchi et al.	
		US- 5,487,992	01/30/1996	Capecchi et al.	
		US- 5,574,205	11/12/1998	Kucheralapati et al.	
		US- 5,578,461	11/26/1996	Sherwin et al.	
		US- 5,591,825	01/07/1997	Gerson et al.	
		US- 5,612,206	03/18/1997	Valerio et al.	
		US- 5,627,059	05/06/1997	Capecchi et al.	
		US- 5,631,153	05/20/1997	Capecchi et al.	
		US- 5,641,670	06/24/1997	Treco et al.	
QW		US- 5,650,148	07/22/1997	Gage et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ - Number ³ - Kind Code ³ (if known)				
QW		WO 96/04397	02/15/1996	Anvret et al.		

Examiner
SignatureDate
Considered

11/18/08

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	To be assigned
		Filing Date	
		First Named Inventor	Rao et al.
		Group Art Unit	To be assigned 1633
		Examiner Name	To be assigned Quany Nguyen
Sheet 2 of 4	Attorney Docket Number	2923-5456.1US	

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
QW		US- 5,750,376	05/12/1998	Weiss et al.	
		US- 5,753,491	05/19/1998	Major et al.	
		US- 5,753,505	05/19/1998	Luskin	
		US- 5,762,926	06/09/1998	Gage et al.	
		US- 5,830,651	11/03/1998	Cauley et al.	
		US- 5,849,553	12/15/1998	Anderson et al.	
		US- 5,869,463	02/09/1999	Major et al.	
		US- 5,928,638	07/27/1999	Uchida et al.	
		US- 5,928,947	07/27/1999	Anderson et al.	
		US- 5,968,502	10/19/1999	Treco et al.	
		US- 5,981,214	11/9/1999	Skoultschi	
		US- 6,077,829	06/20/2000	Tanaka et al.	
		US- 6,093,802	07/25/2000	Lin et al.	
		US- 6,139,835	10/31/2000	Kucheralapati et al.	
		US- 6,204,061 B1	03/20/2001	Capeocchi et al.	
		US- 6,221,376 B1	04/24/2001	Lin et al.	
		US- 6,251,669 B1	06/26/2001	Luskin	
		US- 6,270,989 B1	08-07-2001	Treco et al.	
		US- 6,312,957 B1	11/06/2001	Einerhand et al.	
		US- 6,339,065 B1	01/15/2002	Cooper	
		US- 6,355,239 B1	03/12/2002	Bruder et al.	
		US- 6,355,241 B1	03/12/2002	Sekden et al.	
		US- 6,382,319 B1	03/26/2002	Lin et al.	
QW		US- 6,436,387 B1	08/20/2002	Bauer et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
QW		08298219 (Japanese Abstract)	05/12/1998	Mitsui		

Examiner Signature		Date Considered	11/18/05
-----------------------	---	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known

Application Number	To be assigned
Filing Date	
First Named Inventor	Rao et al.
Group Art Unit	To be assigned 1633
Examiner Name	To be assigned [Signature]
Attorney Docket Number	2923-5456.1US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
QW		AGAH et al., "Gene Recombination in Postmitotic Cells," J. Clin. Invest., July 1997, pp. 169-79, Vol. 100, No. 1.	
		ARBONES et al., "Gene Targeting in Normal Somatic Cells: Inactivation of the Interferon- γ Receptor in Myoblasts," Nature Genetics, Vol. 6, Jan. 1994, pp. 90-159).	
		BUNZ et al., "Targeted Inactivation of p53 in Human Cells Does Not Result in Aneuploidy," Cancer Research 62, Feb. 15, 2002, pp. 1129-1133.	
		CONG et al., "Human Telomerase and Its Regulation," Microbiol. Mol. Biol. Rev., Sept. 2002, pp. 407-425.	
		COPELAND et al., "Recombineering: A Powerful New Tool for Mouse Functional Genomics," Nature Reviews/Genetics, Vol. 2, Oct. 2001, pp. 769-779.	
		COURT et al., "Genetic Engineering Using Homologous Recombination," Annu. Rev. Genet. 2002, 36:361-88.	
		HANSON et al., "Analysis of Biological Selections for High-Efficiency Gene Targeting," Mol. Cell. Biol., Jan. 1995, pp. 45-51.	
		HANSON et al., "Effects of c-myc Expression on Cell Cycle Progression," Mol. Cell. Biol., Sept. 1994, pp. 5748-5755.	
		LINNEY et al., "DNA Fragments from F9 PyEC Mutants Increase Expression of Heterologous Genes in Transfected F9 Cells," Cell, December 1983, pp. 693-99, Vol. 35.	
		PROUTY et al., "A Cell Culture Model System for Genetic Analyses of the Cell Cycle by Targeted Homologous Recombination," Oncogene (1993) 8, pp. 899-907.	
		RAO et al., "A Tripotential Glial Precursor Cell is Present in the Developing Spinal Cord," Proc. Natl. Acad. Sci. USA, Vol. 95:3996-4001, March 1998.	
		RAO et al., "Glial-Restricted Precursors Are Derived from Multipotent Neuroepithelial Stem Cells," Developmental Biology, 188:48-63, 1997.	
QW		SEDIVY, John M., "Can Ends Justify the Means?: Telomeres and the Mechanisms of Replicative Senescence and Immortalization in Mammalian Cells," Proc. Natl. Acad. Sci. USA, Vol. 95:9078-9081, Aug. 1998.	

Examiner Signature	[Signature]	Date Considered	11/18/05
--------------------	-------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known

Application Number	To be assigned
Filing Date	
First Named Inventor	Rao et al.
Group Art Unit	To be assigned 1633
Examiner Name	To be assigned Quang Nguyen
Attorney Docket Number	2923-5456.1US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RN		SOMMER et al., "Neural Stem Cells and Regulation of Cell Number," Progress in Neurobiology, 66:1-18 (2002).	
		THOMAS et al., "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells," Cell, November 6, 1987, pp. 503-512, Vol. 51.	
		WU et al., "Isolation of a Glial-Restricted Tripotential Cell Line From Embryonic Spinal Cord Cultures," GLIA 38:65-79 (2002).	
		YANEZ et al., "Differential Effects of Rad52p Overexpression on Gene Targeting and Extrachromosomal Homologous Recombination in a Human Cell Line," Nucleic Acids Research, 2002, Vol. 30, No. 3, pp. 740-748.	
		YANEZ et al., "Influence of DNA Delivery Method on Gene Targeting Frequencies in Human Cells," Somatic Cell and Molecular Genetics, Vol. 25, No. 1, 1999, pp. 27-31.	
		YANEZ et al., "Therapeutic Gene Targeting," Gene Therapy, 1998, 5, pp. 149-159.	
RN		YANEZ et al., "Uracil Incorporation Into a Gene Targeting Construct Reduces the Frequency of Homologous and Nonhomologous Recombinants in Human Cells," Mutation Research 461, 2000, pp. 157-162.	

Examiner Signature		Date Considered	11/18/05
-----------------------	---	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/789,465
Filing Date	February 27, 2004
First Named Inventor	Rao et al.
Group Art Unit	1636 1633
Examiner Name	To be assigned [Signature]
Attorney Docket Number	2923-5456 111S

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
QN		KEYOUNG et al., High-yield selection and extraction of two promoter-defined phenotypes f neural stem cells from the fetal human brain, Nature Biotechnology, September 2001, pp. 843-50, Vol. 19.	
QN		ROY et al., Telomerase Immortalization of neuronally restricted progenitor cells derived from the human fetal spinal cord, Nature Biotechnology, March 2004, pp. 297-303, Vol. 22, No. 3.	

Examiner Signature	[Signature]	Date Considered	11/28/05
-----------------------	-------------	--------------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.